Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02125253 · ClinicalTrials.gov registry record · Phase 3
Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis
A Phase 3 study, sponsored by Amneal Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 811
- Enrollment target
NCT02125253 is a Phase 3 study that has completed, run by Amneal Pharmaceuticals. The registered enrollment target is 811 participants.
The verdict
NCT02125253, a Phase 3 study, has completed, sponsored by Amneal Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 811 participants
- Enrollment target
Study Summary
To evaluate the therapeutic equivalence of the lest formulation of Mometasone Furoate Nasal Spray, 50 mcg to the marketed formulation NASONEX® (mometasone furoate monohydrate) Nasal Spray, 50 mcg/actuation in patients with seasonal allergic rhinitis
Interventions
- DRUG Placebo Nasal Spray
- DRUG Mometasone Furoate Nasal Spray, 50 mcg
- DRUG Nasonex Nasal Spray, 50 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 811 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02125253
The ClinicalTrials.gov registry entry for NCT02125253 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 811 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amneal Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Nasal Spray is the first listed.
NCT02125253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02125253 about?
NCT02125253 is a clinical study titled "Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis". To evaluate the therapeutic equivalence of the lest formulation of Mometasone Furoate Nasal Spray, 50 mcg to the marketed formulation NASONEX® (mometasone furoate monohydrate) Nasal Spray, 50 mcg/actuation in patients with seasonal allergic rhinitis
What is the current status of trial NCT02125253?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 811 participants. The study started on 2014-01. Estimated completion is 2014-06.
What interventions are being tested in trial NCT02125253?
The interventions under investigation include: Placebo Nasal Spray (DRUG), Mometasone Furoate Nasal Spray, 50 mcg (DRUG), Nasonex Nasal Spray, 50 mcg (DRUG).
Who is sponsoring clinical trial NCT02125253?
This trial is sponsored by Amneal Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.